Drug intelligence / Profile preview

OASIT-K

Development stage: Unknown
Lead developer: Bio-STILOGIT Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

OASIT-K is a dietary supplement developed and marketed by Bio-STILOGIT Pharmaceuticals, primarily indicated for the prevention and management of nephrolithiasis (kidney stones). The formulation typically contains potassium citrate and magnesium citrate, which serve as urinary alkalizing agents. By increasing urinary pH and citrate concentration, OASIT-K helps to inhibit the nucleation, growth, and aggregation of calcium oxalate and calcium phosphate crystals, which are the most common components of renal calculi. It is sold as a retail consumer health product, particularly in the Italian market, to support urinary tract health and prevent stone recurrence in patients with hypocitraturia or acidic urine.

Brand names: OASIT-K

Targets

Hydroxyapatite

Beyond the preview

Go deeper on OASIT-K.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OASIT-K.

Explore the full profile